The growth of Anatomic Pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on personalized medicine. In addition, emerging economies such as China, India, and Brazil are expected to offer significant growth opportunities for players operating in the market during the forecast period.
According to the new market research report global anatomic pathology market is projected to reach $ 49.1 billion by 2026 from $ 35.1 billion in 2021, at a CAGR of 7.0%.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137323145
OPPORTUNITY: Increasing number of clinical trials pertaining to cancer drugs
Anatomic pathology products and services are used in oncology drug trials to analyze quantitative information, detect morphological structures, detect pharmacodynamic markers, and understand drug mechanisms. It is also used to stratify trial subjects based on the responses given by tissues to the drugs. Tissue diagnostics thus enable efficient trials and retrospective studies by reducing the cost and time involved in these processes. For example, in a Phase III study for Roche’s cancer immunotherapy—TECENTRIQ (atezolizumab)—the PD-L1 (programmed death-ligand 1) expression was assessed using an investigational immunohistochemistry (IHC) test, which was developed by Roche Tissue Diagnostics.
- Hoffmann-La Roche AG (Switzerland) was the leading player in the anatomic pathology market in 2020. The company has a wide range of products in the consumables segment. Strong business operations across all key regions, coupled with a strong brand image, make the firm a leading player in this market. F. Hoffman-La Roche has adopted organic business strategies such as product launches in order to maintain its leading position in the anatomic pathology market
Recent Developments:
- In May 2021, Hologic received premarket approval (PMA) from the FDA for its ThinPrep GenesisTM processor for cytology processing and specimen transfer for downstream applications.
- PHC Holding Corporation completed the acquisition of Thermo Fisher Scientific’s Anatomical Pathology business to strengthen its position in the diagnostics segment.
Request For Free Report Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=137323145
The study involved four major activities in estimating the current size of the anatomic pathology market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.
